• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Liver transplantation for hepatocellular carcinoma: a proposal of a prognostic scoring system.肝细胞癌的肝移植:一种预后评分系统的提议
J Am Coll Surg. 2000 Oct;191(4):389-94. doi: 10.1016/s1072-7515(00)00688-8.
2
Predictors of long-term survival after liver transplantation for hepatocellular carcinoma.肝细胞癌肝移植术后长期生存的预测因素。
Am J Gastroenterol. 2005 Dec;100(12):2708-16. doi: 10.1111/j.1572-0241.2005.00289.x.
3
Predictive model for microvascular invasion of hepatocellular carcinoma among candidates for either hepatic resection or liver transplantation.肝癌肝切除或肝移植候选者微血管侵犯的预测模型。
Surgery. 2019 Jun;165(6):1168-1175. doi: 10.1016/j.surg.2019.01.012. Epub 2019 Mar 14.
4
Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation.肝细胞癌组织学分级对肝移植结局的影响。
Arch Surg. 2001 Jan;136(1):25-30; discussion 31.
5
Is the pathologic TNM staging system for patients with hepatoma predictive of outcome?肝癌患者的病理TNM分期系统能否预测预后?
Cancer. 2000 Feb 1;88(3):538-43. doi: 10.1002/(sici)1097-0142(20000201)88:3<538::aid-cncr7>3.0.co;2-h.
6
Outcomes of liver transplantation in 490 patients with hepatocellular carcinoma: validation of a uniform staging after surgical treatment.490例肝细胞癌患者肝移植的结果:手术治疗后统一分期的验证
J Am Coll Surg. 2007 May;204(5):1016-27; discussion 1027-8. doi: 10.1016/j.jamcollsurg.2006.12.043.
7
Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation.供体肝移植后肝细胞肝癌患者的临床结局。
World J Gastroenterol. 2013 Aug 7;19(29):4737-44. doi: 10.3748/wjg.v19.i29.4737.
8
Is liver resection justified in advanced hepatocellular carcinoma? Results of an observational study in 464 patients.晚期肝细胞癌行肝切除术是否合理?464例患者的观察性研究结果
J Gastrointest Surg. 2009 Jul;13(7):1313-20. doi: 10.1007/s11605-009-0903-x. Epub 2009 May 6.
9
A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.一种新型预后列线图可准确预测肝移植后肝细胞癌复发:对865例连续肝移植受者的分析
J Am Coll Surg. 2015 Apr;220(4):416-27. doi: 10.1016/j.jamcollsurg.2014.12.025. Epub 2014 Dec 27.
10
Prediction of recurrence and prognosis in patients with hepatocellular carcinoma after resection by use of CLIP score.利用CLIP评分预测肝细胞癌患者切除术后的复发及预后
World J Gastroenterol. 2002 Apr;8(2):237-42. doi: 10.3748/wjg.v8.i2.237.

引用本文的文献

1
Clinical Nomogram Model for Pre-Operative Prediction of Microvascular Invasion of Hepatocellular Carcinoma before Hepatectomy.临床列线图模型预测肝癌切除术前行微血管侵犯的术前预测。
Medicina (Kaunas). 2024 Aug 28;60(9):1410. doi: 10.3390/medicina60091410.
2
Criteria and prognostic models for patients with hepatocellular carcinoma undergoing liver transplantation.接受肝移植的肝细胞癌患者的标准和预后模型
Clin Mol Hepatol. 2025 Feb;31(Suppl):S285-S300. doi: 10.3350/cmh.2024.0323. Epub 2024 Aug 19.
3
Macroscopic Characterization of Hepatocellular Carcinoma: An Underexploited Source of Prognostic Factors.肝细胞癌的宏观特征:一个未被充分利用的预后因素来源
J Hepatocell Carcinoma. 2024 Apr 6;11:707-719. doi: 10.2147/JHC.S447848. eCollection 2024.
4
Impact of Pre-Liver Transplant Treatments on the Imaging Accuracy of HCC Staging and Their Influence on Outcomes.肝移植前治疗对肝癌分期影像准确性的影响及其对预后的影响。
Cancers (Basel). 2024 Mar 4;16(5):1043. doi: 10.3390/cancers16051043.
5
Transplant Oncology: An Emerging Discipline of Cancer Treatment.移植肿瘤学:癌症治疗的一门新兴学科。
Cancers (Basel). 2023 Nov 9;15(22):5337. doi: 10.3390/cancers15225337.
6
Characterization of somatic mutations and pathway alterations during hepatocellular carcinoma vascular invasion using next-generation sequencing.使用二代测序技术对肝细胞癌血管侵犯过程中的体细胞突变和信号通路改变进行特征分析。
J Gastrointest Oncol. 2022 Aug;13(4):1864-1874. doi: 10.21037/jgo-22-556.
7
Different Models to Predict the Risk of Recurrent Hepatocellular Carcinoma in the Setting of Liver Transplantation.预测肝移植后复发性肝细胞癌风险的不同模型
Cancers (Basel). 2022 Jun 16;14(12):2973. doi: 10.3390/cancers14122973.
8
R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation.R3-AFP评分是一种新的综合工具,用于优化肝移植后肝细胞癌复发的预测。
JHEP Rep. 2022 Feb 2;4(5):100445. doi: 10.1016/j.jhepr.2022.100445. eCollection 2022 May.
9
Risk Score Model for Microvascular Invasion in Hepatocellular Carcinoma: The Role of Tumor Burden and Alpha-Fetoprotein.肝细胞癌微血管侵犯的风险评分模型:肿瘤负荷和甲胎蛋白的作用
Cancers (Basel). 2021 Aug 31;13(17):4403. doi: 10.3390/cancers13174403.
10
Hepatocellular cancer selection systems and liver transplantation: from the tower of babel to an ideal comprehensive score.肝细胞癌选择系统与肝移植:从巴别塔到理想的综合评分。
Updates Surg. 2021 Oct;73(5):1599-1614. doi: 10.1007/s13304-021-01078-4. Epub 2021 May 18.

本文引用的文献

1
Is the pathologic TNM staging system for patients with hepatoma predictive of outcome?肝癌患者的病理TNM分期系统能否预测预后?
Cancer. 2000 Feb 1;88(3):538-43. doi: 10.1002/(sici)1097-0142(20000201)88:3<538::aid-cncr7>3.0.co;2-h.
2
Should hepatomas be treated with hepatic resection or transplantation?肝癌应该采用肝切除术还是肝移植术进行治疗?
Cancer. 1999 Oct 1;86(7):1151-8. doi: 10.1002/(sici)1097-0142(19991001)86:7<1151::aid-cncr8>3.0.co;2-v.
3
Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors.肝细胞癌根治性切除术后肝内复发:治疗的长期结果及预后因素
Ann Surg. 1999 Feb;229(2):216-22. doi: 10.1097/00000658-199902000-00009.
4
Long term prognosis after hepatectomy for hepatocellular carcinoma: a survival analysis of 204 consecutive patients.肝细胞癌肝切除术后的长期预后:204例连续患者的生存分析
Cancer. 1998 Dec 1;83(11):2302-11.
5
Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power.小肝细胞癌的肝移植:肿瘤-淋巴结-转移分类无预后预测价值。
Hepatology. 1998 Jun;27(6):1572-7. doi: 10.1002/hep.510270616.
6
Survival and recurrence after liver transplantation versus liver resection for hepatocellular carcinoma: a retrospective analysis.肝细胞癌肝移植与肝切除术后的生存及复发情况:一项回顾性分析
Ann Surg. 1998 Mar;227(3):424-32. doi: 10.1097/00000658-199803000-00015.
7
Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation.采用肝次全切除术或肝移植治疗纤维板层样肝癌。
Hepatology. 1997 Oct;26(4):877-83. doi: 10.1002/hep.510260412.
8
The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study.原位肝移植后肝细胞癌复发风险及复发时间的预测:一项初步研究。
Hepatology. 1997 Aug;26(2):444-50. doi: 10.1002/hep.510260227.
9
Recurrence of hepatocellular carcinoma after surgery.肝细胞癌术后复发
Br J Surg. 1996 Sep;83(9):1219-22.
10
Hepatocellular carcinoma and cirrhosis. Results of surgical treatment in a European series.肝细胞癌与肝硬化。欧洲系列手术治疗结果
Ann Surg. 1996 Mar;223(3):297-302. doi: 10.1097/00000658-199603000-00011.

肝细胞癌的肝移植:一种预后评分系统的提议

Liver transplantation for hepatocellular carcinoma: a proposal of a prognostic scoring system.

作者信息

Iwatsuki S, Dvorchik I, Marsh J W, Madariaga J R, Carr B, Fung J J, Starzl T E

机构信息

Department of Surgery, Thomas E Starzl Transplantation Institute, University of Pittsburgh Medical Center, PA 15213, USA.

出版信息

J Am Coll Surg. 2000 Oct;191(4):389-94. doi: 10.1016/s1072-7515(00)00688-8.

DOI:10.1016/s1072-7515(00)00688-8
PMID:11030244
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2966013/
Abstract

BACKGROUND

The current staging system of hepatocellular carcinoma established by the International Union Against Cancer and the American Joint Committee on Cancer does not necessarily predict the outcomes after hepatic resection or transplantation.

STUDY DESIGN

Various clinical and pathologic risk factors for tumor recurrence were examined on 344 consecutive patients who received hepatic transplantation in the presence of nonfibrolamellar hepatocellular carcinoma to establish a reliable risk scoring system.

RESULTS

Multivariate analysis identified three factors as independently significant poor prognosticators: 1) bilobarly distributed tumors, 2) size of the greatest tumor (2 to 5 cm and > 5 cm), and 3) vascular invasion (microscopic and macroscopic). Prognostic risk score (PRS) of each patient was calculated from the relative risks of multivariate analysis. The patients were grouped into five grades of tumor recurrence risk: grade 1: PRS = 0 to < 7.5; grade 2: PRS = 7.5 to < or = 11.0; grade 3: PRS > 11.0 to 15.0; grade 4: PRS > or = 15.0; and grade 5: positive node, metastasis, or margin. The proposed PRS system correlated extremely well with tumor-free survival after liver transplantation (100%, 61%, 40%, 5%, and 0%, from grades 1 to 5, respectively, at 5 years), but current pTNM staging did not.

CONCLUSIONS

  1. Patients with grades 1 and 2 are effectively treated with liver transplantation, 2) patients with grades 4 and 5 are poor candidates for liver transplantation, and 3) patients with grade 1 do not benefit from adjuvant chemotherapy.
摘要

背景

国际抗癌联盟和美国癌症联合委员会制定的现行肝细胞癌分期系统不一定能预测肝切除或肝移植后的预后。

研究设计

对344例接受非纤维板层型肝细胞癌肝移植的连续患者,研究了肿瘤复发的各种临床和病理危险因素,以建立一个可靠的风险评分系统。

结果

多因素分析确定了三个独立的显著不良预后因素:1)双叶分布肿瘤;2)最大肿瘤大小(2至5厘米和>5厘米);3)血管侵犯(显微镜下和肉眼可见)。根据多因素分析的相对风险计算每位患者的预后风险评分(PRS)。患者被分为五个肿瘤复发风险等级:1级:PRS = 0至<7.5;2级:PRS = 7.5至<或=11.0;3级:PRS>11.0至15.0;4级:PRS>或=15.0;5级:阳性淋巴结、转移或切缘阳性。所提出的PRS系统与肝移植后的无瘤生存率相关性极佳(5年时,1至5级分别为100%、61%、40%、5%和0%),但现行的pTNM分期则不然。

结论

1)1级和2级患者行肝移植可有效治疗;2)4级和5级患者不是肝移植的合适候选者;3)1级患者不能从辅助化疗中获益。